The biosensor, also relevant for the detection of several other human pathologies, has been designed and developed by the Molecular and Precision Oncology laboratory of Biogem (Ariano Irpino), directed by Professor Michele Caraglia, at the beginning of 2023, and it will be presented in Lille, during the thirteenth edition of Biofit, one of the most important European events in the life sciences. The French meeting, which will take place on December 3rd and 4th, aims to close the gap between research and industries, and to encourage the creation of networks between public and private players in the sector. An objective constantly pursued by Biogem, represented in Lille by its International Marketing Director, Michele Farisco, who has already 'booked' over thirty face-to-face meetings with representatives of institutes and companies in the biotechnology sector.
<<The biosensor we invented – says Professor Caraglia – is a disposable and low-cost analytical support, it is made of electro-spinned nanofibers, and it is directed towards miRNA targets relevant for the diagnosis and prognosis of different pathologies>>.
Designed by a team of researchers including, among others, in addition to Caraglia himself, Marianna Scrima and Alessia Maria Cossu (also from the oncology research area of Biogem), CNR researchers Luca De Stefano, Ilaria Rea and Sara Martino, and Professor Gabriella Misso from the Vanvitelli University, the new patented biosensor, mainly targeting the biomedical and health market, especially the oncology sector, <<has the advantages – Caraglia further emphasizes – of rather low production costs and manufacturing technologies compatible with large-scale industrial production>>.
<<Biofit – says Michele Farisco – will be the perfect place to promote the Biogem preclinical services, especially the test activities on potential new drugs, performed by our GLP-certified Test Facility>>. <<A cutting-edge facility – Farisco finally outlines – for the production of proteins and antibodies and for the several efficacy studies on in vitro and on animal oncology models>>.
